Breaking News

You are here » Indian-Commodity  :  Corporate  :  Zydus Cadila receives final approval from USFDA for Doxycycline Hyclate Tablets

31-Oct2017

Zydus Cadila receives final approval from USFDA for Doxycycline Hyclate Tablets

Zydus Cadila has received the final approval from the US Food & Drug Administration (USFDA) to market Doxycycline Hyclate Tablets USP, 100 mg. The drug is a broad spectrum antibiotic and is indicated to treat or prevent a variety of infectious disorders that are proven or strongly suspected to be caused by susceptible bacteria.

The tablets will be manufactured at the group's formulations manufacturing facility at SEZ, Ahmedabad. The group now has more than 165 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.


Related News

View all news

NCLT levies penalty on Tata Chemicals

The National Company Law Tribunal (NCLT) Mumbai, has levied a penalty of Rs 10 lakh on Tata Chemicals for filing a petition fraudulently and with malicious intent to liquidate Raj Process Equipment and......

Reliance Industries' arms to launch new e-commerce platform

Reliance Industries' group companies--Reliance Jio and Retail will launch a new e-commerce platform in the country. This project will empower 12 lakh small retailers in Gujarat.Reliance Industries is India's......

Glenmark Pharma recalling 96,240 applicators of its product from US

Glenmark Pharmaceuticals is recalling 96,240 applicators of its product Estradiol vaginal inserts for defective delivery system. The USFDA has termed it as a Class-II recall. The USFDA has classified Class-II......

Top News

View all news

Glenmark Pharma recalling 96,240 applicators of its product from US

Glenmark Pharmaceuticals is recalling 96,240 applicators of its product Estradiol vaginal inserts for defective delivery system. The USFDA has termed it as a Class-II recall. The USFDA has classified Class-II......

Infosys hires over 7,600 staff in US

Infosys has hired over 7,600 staff in the US. This hiring is more than three-fourth of its target of recruiting 10,000 American workers. The company is making recruitment from local schools a 'sustained......

SBI to sell 26% stake of SBI payment services

State Bank of India (SBI) is planning to sell 26% stake of its SBI payment services (SPSPL) to Hitachi Payment Services (HPY). After allotment of the shares, SBI shareholding in SPSPL will become 74% from......